Stephanie Müller, Luise Tittl, Victoria Speed, Lara Roberts, Jignesh Patel, Raj Patel, Roopen Arya, Nils Kucher, David Spirk, Kurtulus Sahin, Jan Beyer-Westendorf
Background: The direct factor Xa inhibitor rivaroxaban is approved for the treatment of venous thromboembolism (VTE), based on the results of large phase III trials. Objectives: To confirm rivaroxaban's effectiveness and safety in routine clinical care of patients with VTE. Methods: Data were obtained from prospective, noninterventional registries: the FIRST registry (United Kingdom), DRESDEN NOAC registry (Germany), and SWIVTER (Switzerland)...
October 2022: Research and Practice in Thrombosis and Haemostasis